Oxygenta Pharmaceutical Q2 Results FY27: Revenue Up 134.2%, Loss Narrows 44.42%, PAT Rs -2.74 Cr
- November 10, 2026
- Posted by: Harsh Piplani
- Category: Results
Quick Answer
Oxygenta Pharmaceutical Q2 Results FY27 were declared on 10 November 2026 for the July to September 2026 quarter on a Standalone basis. Oxygenta Pharmaceutical reported revenue of Rs 33.49 Cr, up 134.2% YoY from Rs 14.3 Cr, and a net loss of Rs 2.74 Cr, which is net profit of Rs -2.74 Cr against Rs -4.93 Cr a year earlier. The quarterly results therefore show YoY growth in revenue and a smaller loss. Univest explains the numbers below.
Oxygenta Pharmaceutical Ltd (OXYGENTAPH) Q2 Results FY27 announced on 10 November 2026, covering the company’s financial performance for the July to September quarter. Revenue was Rs 33.49 Cr against Rs 14.3 Cr a year earlier, while net profit was Rs -2.74 Cr against Rs -4.93 Cr. With the results date on record, the Oxygenta Pharmaceutical Q2 Results FY27 standalone results are compared with the same quarter last year.
This Oxygenta Pharmaceutical Q2 Results analysis covers the financial highlights, business drivers, outlook and risks behind the numbers. The results analysis begins with the Financial Highlights table, which sets the July to September 2026 standalone results against the corresponding quarter of the previous year.
Click Here – Get Free Investment Predictions
Oxygenta Pharmaceutical Q2 Results FY27: Financial Highlights
| Metric | Q2 FY27 (Sep 26) | Q2 FY26 (Sep 25) | YoY Change |
|---|---|---|---|
| Revenue | Rs 33.49 Cr | Rs 14.3 Cr | +134.2% YoY |
| Operating Profit | Rs 0.03 Cr | Rs -4.57 Cr | +100.66% YoY |
| Net Profit (PAT) | Rs -2.74 Cr | Rs -4.93 Cr | +44.42% YoY |
Source: company filing for Oxygenta Pharmaceutical Q2 Results FY27, 10 November 2026. Figures in Rs Crore, Standalone basis.
Key Takeaways from Oxygenta Pharmaceutical Q2 Results: What Stands Out
- Revenue of Rs 33.49 Cr grew 134.2% YoY from Rs 14.3 Cr in the same quarter last year, reported on a Standalone basis.
- Operating Profit of Rs 0.03 Cr compared with Rs -4.57 Cr a year earlier, a YoY change of 100.66% within Oxygenta Pharmaceutical Q2 Results FY27.
- Net profit of Rs -2.74 Cr compared with Rs -4.93 Cr a year earlier, so the net loss narrowed by 44.42% YoY.
- Net profit margin of -8.2% improved from -34.5% in the comparison quarter, so the loss as a share of revenue shrank.
- Return on capital employed of -33.53% in FY26 is among the risks flagged, which the performance analysis weighs next.
Oxygenta Pharmaceutical Q2 Results FY27: Performance Analysis
Oxygenta Pharmaceutical reported revenue of Rs 33.49 Cr, Operating Profit of Rs 0.03 Cr and net profit of Rs -2.74 Cr for the July to September 2026 quarter. Revenue grew 134.2% YoY, while Operating Profit moved from Rs -4.57 Cr and the net loss narrowed from Rs -4.93 Cr a year earlier.
Oxygenta Pharmaceutical Q2 Results FY27 imply a revenue increase of Rs 19.19 Cr, an Operating Profit gain of Rs 4.6 Cr and a net loss reduction of Rs 2.19 Cr against the same quarter last year. This results analysis notes that the declared figures confirm the size of the YoY growth but do not establish the specific cause of it.
The Oxygenta Pharmaceutical Q2 Results standalone results also show net profit margin at -8.2% against -34.5%, so revenue more than doubled while the loss shrank. Univest readers can track the next quarterly results against these Q2 numbers. That brings the analysis to the business factors listed for the quarter.
Check the Univest Screener for live results data
Key Business Factors This Quarter
Revenue Growth – The business factors behind Oxygenta Pharmaceutical Q2 Results FY27 begin with revenue growth of 134.2% YoY to Rs 33.49 Cr, up from Rs 14.3 Cr, which forms the top line for this quarter’s standalone results and the base against which the loss figures are read.
Net Profit Margin – Net profit margin improved to -8.2% from -34.5% in the comparison quarter, which means the net loss of Rs 2.74 Cr is a smaller share of revenue than the Rs 4.93 Cr loss was a year earlier.
Debt Position – The company is almost debt free, with a debt-to-assets ratio of -2.57 in FY26, so the quarterly results are read against a minimal debt position rather than a borrowing-led balance sheet.
FY27 Outlook After Oxygenta Pharmaceutical Q2 Results
Full-year FY27 results will depend on the quarters that follow Oxygenta Pharmaceutical Q2 Results FY27, and the next quarterly disclosures will show whether the July to September pattern on a standalone basis continues. This results analysis keeps to the declared figures and does not project forward revenue or profit numbers.
The net profit of Rs -2.74 Cr reported for this quarter sits against a return on capital employed of -33.53% in FY26, so each new filing becomes a fresh reference point for the loss trend. Univest Screener can be used to follow those filings, and the risks to watch come next.
Key Risks to Watch After Oxygenta Pharmaceutical Q2 Results FY27
Net Loss
Company reported a net loss of Rs 2.74 Cr in the latest quarter, and Oxygenta Pharmaceutical Q2 Results FY27 show that this loss remains the central item even though it is smaller than the Rs 4.93 Cr loss of the year before.
Return on Equity
Return on equity was low at 0.00% in FY26, which means the annual returns measure shows no return even as the quarterly YoY growth in revenue and the narrower loss are visible in these quarterly results.
Return on Capital Employed
Return on capital employed was modest at -33.53% in FY26, so the annual capital efficiency measure stays negative, and investors will want to see later quarters set against this FY26 reference.
Download the Univest iOS App or Univest Android App to track quarterly results as they are declared.
Conclusion
Oxygenta Pharmaceutical Q2 Results FY27 show revenue of Rs 33.49 Cr, up 134.2% YoY, and a smaller net loss of Rs 2.74 Cr on a Standalone basis. The quarterly results and standalone results are best read alongside upcoming filings, and investors should consult a SEBI-registered advisor before acting. This Oxygenta Pharmaceutical Q2 Results summary is informational only.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice. Research Analyst: Uniresearch Global Pvt. Ltd., SEBI Registration No. INH000013776.
Frequently Asked Questions on Oxygenta Pharmaceutical Q2 Results FY27
What are Oxygenta Pharmaceutical Q2 Results FY27?
Ans. Oxygenta Pharmaceutical Q2 Results FY27 cover the July to September 2026 quarter on a Standalone basis, with revenue of Rs 33.49 Cr and net profit of Rs -2.74 Cr, while Financial Highlights sets out the full comparison.
What is the results date for Oxygenta Pharmaceutical Q2 Results FY27?
Ans. The results date for Oxygenta Pharmaceutical Q2 Results FY27 is 10 November 2026, which means the figures reflect the July to September quarter, as explained in the opening paragraphs of this results analysis.
What revenue was reported in Oxygenta Pharmaceutical Q2 Results FY27?
Ans. Oxygenta Pharmaceutical reported revenue of Rs 33.49 Cr in the quarter, compared with Rs 14.3 Cr a year earlier, so the Performance Analysis section covers the Rs 19.19 Cr revenue increase in detail.
What net profit was reported in Oxygenta Pharmaceutical Q2 Results FY27?
Ans. Oxygenta Pharmaceutical reported net profit of Rs -2.74 Cr for the quarter, a net loss, compared with Rs -4.93 Cr in the same quarter last year, as covered in the Key Takeaways section.
How much YoY growth did revenue show in Oxygenta Pharmaceutical Q2 Results FY27?
Ans. Revenue showed YoY growth of 134.2%, rising from Rs 14.3 Cr to Rs 33.49 Cr, which means the top line expanded while the loss narrowed, as highlighted in the Key Takeaways section.
Did net profit rise or fall in Oxygenta Pharmaceutical Q2 Results?
Ans. Net profit improved in Oxygenta Pharmaceutical Q2 Results, as the net loss narrowed from Rs 4.93 Cr to Rs 2.74 Cr, a 44.42% YoY change, so the Performance Analysis section compares this with the revenue move.
What was the Operating Profit in Oxygenta Pharmaceutical Q2 Results FY27?
Ans. Operating Profit was Rs 0.03 Cr in Oxygenta Pharmaceutical Q2 Results FY27, against Rs -4.57 Cr a year earlier, a 100.66% YoY change, so the operating result moved higher, as detailed in Key Business Factors.
Are Oxygenta Pharmaceutical Q2 Results consolidated results or standalone results?
Ans. Oxygenta Pharmaceutical Q2 Results are standalone results, as the filing reports on a Standalone basis, so the figures cover the company on its own, as noted in the opening paragraphs of this article.
What business factors shaped Oxygenta Pharmaceutical Q2 Results FY27?
Ans. The business factors for Oxygenta Pharmaceutical Q2 Results FY27 are the 134.2% revenue growth to Rs 33.49 Cr, the net profit margin moving to -8.2% from -34.5% and the low debt position, per Key Business Factors.
What are the key risks after Oxygenta Pharmaceutical Q2 Results FY27?
Ans. The key risks after Oxygenta Pharmaceutical Q2 Results FY27 are the Rs 2.74 Cr net loss, the FY26 return on equity of 0.00% and return on capital employed of -33.53%, so the Key Risks section covers each.
What is the outlook after Oxygenta Pharmaceutical Q2 Results?
Ans. The outlook after Oxygenta Pharmaceutical Q2 Results depends on the quarters that follow in FY27, while the declared figures are covered without forward projections, as explained in the FY27 Outlook section.
Where can I find the complete Oxygenta Pharmaceutical Q2 Results FY27 data?
Ans. The complete Oxygenta Pharmaceutical Q2 Results FY27 data is in the Financial Highlights table of this article, and the Univest Screener can be used to follow later quarterly results alongside it.
